ProMIS Neurosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET INCOME (LOSS) PER SHARE (Tables)

NET INCOME (LOSS) PER SHARE (Tables)

9 Months Ended

Sep. 30, 2024

NET INCOME (LOSS) PER SHARE

Summary of computation of basic and diluted net income (loss) per share attributable to common shareholders


		Three Months Ended September 30,						Nine Months Ended September 30,
		2024			2023			2024			2023
Numerator:
Net income (loss)		$	9,275,825		$	(2,360,648)		$	3,017,080		$	(9,632,053)
Denominator:
Basic weighted-average common shares outstanding			30,023,675			12,370,830			22,953,751			9,861,719
Effect of potentially dilutive securities:
Warrants			—			—			696,070			—
Stock options			43,420			—			26,283			—
Diluted weighted-average common shares outstanding			30,067,095			12,370,830			23,676,104			9,861,719

Basic net income (loss) per share attributable to common shareholders		$	0.31		$	(0.19)		$	0.13		$	(0.98)
Diluted net income (loss) per share attributable to common shareholders		$	0.31		$	(0.19)		$	0.13		$	(0.98)

Summary of outstanding potentially dilutive common shares equivalents were excluded from the computation of diluted net income (loss) per share


		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2024		2023		2024		2023
Options issued and outstanding under stock option plan		1,087,493		1,041,492		651,030		1,041,492
Warrants		56,746,647		13,955,897		45,518,933		13,955,897
Series 1 Convertible Preferred Shares		—		1,166,667		—		1,166,667
Deferred Share Units		1,061		1,061		1,061		1,061
Total		57,835,201		16,165,117		46,171,024		16,165,117